Dementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth Analysis – Technavio

Health50 kritiya Dementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth Analysis - Technavio

NEW YORK, Jan. 29, 2024 /PRNewswire/ — The dementia and movement disorder treatment market – Competitive Analysis, Recovery & Impact of COVID-19, Five Force Analysis report has been added to Technavio’s offering. The market is estimated to grow by USD 8.55 billion during 2024-2028, growing at a CAGR of 7.28%Advances in biomedical science are a primary trend in the market. Advanced methodologies such as bioinformatics, molecular targeting, nanotechnology, and personalized medicine have played a crucial role in advancing drug development for neurodegenerative disorders, including dementia. Bioinformatics utilizes mathematical models to deepen our understanding of human systems. 

For Comprehensive details on the market size of historic period(2018 to 2022) and forecast period (2024-2028) – View the Free Sample report

The market is fragmented; the companies are competing with competitors and are trying to get greater market share. The market is growing, and the chances of new entrants cannot be overlooked. The major companies have well-established economies of scale and presence and generally rely on positioning, technological advances, and the price of the products –The report provides a full list of key companies, their strategies, and the latest developments. Buy Now

  • The rising prevalence of target diseases drives growth.
  • Failure rates of drugs in clinical trials is a major challenge hindering the growth.

Technavio has identified key trends, drivers, and challenges, which will help clients improve their strategies to stay ahead of their competitors. – View the Free Sample Report

The report includes information on the product launches, sustainability, and prospects of leading companies including AbbVie Inc., Acorda Therapeutics Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Biogen Inc., Eisai Co. Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Kirin Holdings Co. Ltd., Lannett Co. Inc., Merck and Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Organon and Co., Orion Pharma Ltd., Otsuka Holdings Co. Ltd., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and UCB SA.

Gain instant access to 17,000+ research reports. 

Technavio’s SUBSCRIPTION platform

The report includes competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score and performance score. The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, among others.

The growth by the movement disorders segment is significant during the forecast period. Movement disorders encompass a cluster of neurological conditions that primarily disrupt an individual’s capability to generate and regulate movements. These disorders can have a substantial impact on daily activities and overall life satisfaction. 


In the realm of Dementia and movement disorder treatment applications, the convergence of innovative solutions and therapeutic strategies is paramount. Conditions like Alzheimer’s Disease and Parkinson’s Disease necessitate tailored interventions, with Cholinesterase Inhibitors and Levodopa playing pivotal roles. Deep Brain Stimulation emerges as a sophisticated approach addressing specific movement-related challenges. The integration of Cognitive Behavioral Therapy with pharmacotherapy underscores the importance of mental health, while ongoing Clinical Trials and the identification of Patient Biological Markers drive continuous advancements. The concept of Neuroplasticity guides interventions for managing Motor Symptoms, emphasizing Non-Behavioral Management, and recognizing the invaluable role of Caregiver Support.

Related Reports

The renal anemia therapeutics market size is estimated to grow by USD 2.08 billion, at a CAGR of 7.59% between 2023 and 2028.

The hormone replacement therapy (HRT) market size is estimated to grow by USD 8.44 billion, at a CAGR of 6.67% between 2023 and 2028.

1 Executive Summary

2 Landscape

3 Sizing

4 Historic Size

5 Five Forces Analysis

6 Segmentation by Application

7 Segmentation by Drug Class

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Trends

11 Company Landscape

12 Company Analysis

13 Appendix

About US

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging trends and provide actionable insights to help businesses identify opportunities and develop effective strategies to optimize their positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable insights to identify opportunities in existing and potential markets and assess their competitive positions within changing scenarios.


Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]


Cision View original content to download multimedia:—-technavio-302045378.html

SOURCE Technavio

rt Dementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth Analysis - Technavio

Featured image: © kritiya